Diminished Mycophenolic Acid Exposure Caused by Omeprazole May Be Clinically Relevant in the First Week Posttransplantation
Carregando...
Citações na Scopus
17
Tipo de produção
article
Data de publicação
2012
Título da Revista
ISSN da Revista
Título do Volume
Editora
LIPPINCOTT WILLIAMS & WILKINS
Citação
THERAPEUTIC DRUG MONITORING, v.34, n.3, p.331-336, 2012
Resumo
Background: Some studies have reported a decreased absorption of mycophenolic acid (MPA) from mycophenolate mofetil (MMF) in renal transplanted (RTx) patients under proton-pump inhibitors (PPIs). There is still a lack of information regarding (1) whether this effect occurs when MMF is administered with either tacrolimus or cyclosporine A [calcineurin inhibitors (CNIs)], (2) whether the effect has the same amplitude during the first year after RTx, and finally (3) whether this decrease in exposure is clinically relevant. Methods: We retrospectively analyzed the omeprazole effect in 348 12-hour pharmacokinetic samplings [area under the curve (AUC) 0-12h] performed on days 7, 14, 30, 60, 180, and 360 after RTx in 77 patients who participated in previous trials. Results: For all periods, the groups with and without PPI did not differ in all variables. By mixed-model analysis of variance, PPI reduced the MPA AUC(0-12h) (P < 0.0008) in the patients under both CNIs mainly due to decreased absorption (P = 0.049). In the tacrolimus group, a lower exposure seemed also due to a decreased MPA reabsorption at 10-12 hours. The PPI effect remains throughout the first year but was clinically more important on day 7. By Cox analysis, the use of PPI was associated with a 25% less chance of being adequately exposed to MPA (95% confidence interval 0.58-0.99, P = 0.04). Similarly, the number of patients underexposed to MPA (AUC < 30 ng.h/mL) was higher at most periods in the PPI group but again not statistically significant. Conclusions: These data indicate that PPI decreases the MPA exposure when associated with both CNIs but particularly in the first week after RTx. In this period, the MMF dose should be increased. This effect lasts throughout the first year but does not seem to be clinically relevant after the first week.
Palavras-chave
mycophenolic acid, pharmacokinetic, immunosuppression
Referências
- David-Neto E, 2002, AM J TRANSPL S3, V2, P192
- David-Neto E, 2005, CLIN TRANSPLANT, V19, P19, DOI 10.1111/j.1399-0012.2004.00260.x
- Gaston R, 2009, AM J TRANSPLANT, V9, P1607, DOI 10.1111/j.1600-6143.2009.02668.x
- GEDDA K, 1995, GASTROENTEROLOGY, V109, P1134, DOI 10.1016/0016-5085(95)90571-5
- Haufroid V, 2004, PHARMACOGENETICS, V14, P147, DOI 10.1097/01.pfc.0000114719.42625.e8
- Hesselink DA, 2005, AM J TRANSPLANT, V5, P987, DOI 10.1111/j.1600-6143.2005.00779.x
- Kiberd BA, 2011, THER DRUG MONIT, V33, P120, DOI 10.1097/FTD.0b013e318206a1b1
- Kiberd BA, 2004, AM J TRANSPLANT, V4, P1079, DOI 10.1111/j.1600-6143.2004.00455.x
- Kirchheiner J, 2009, EUR J CLIN PHARMACOL, V65, P19, DOI 10.1007/s00228-008-0576-5
- Kofler S, 2009, J HEART LUNG TRANSPL, V28, P605, DOI 10.1016/j.healun.2009.03.006
- Kofler S, 2009, AM J TRANSPLANT, V9, P1650, DOI 10.1111/j.1600-6143.2009.02682.x
- Kuypers DR, 2011, CLIN J AM SOC NEPHRO, V5, P341
- Le Meur Y, 2007, AM J TRANSPLANT, V7, P2496, DOI 10.1111/j.1600-6143.2007.01983.x
- Lidgate D, 2002, DRUG DEV IND PHARM, V28, P1275, DOI 10.1081/DDC-120015361
- Logan AJ, 2002, CLIN TRANSPLANT, V16, P163, DOI 10.1034/j.1399-0012.2002.01012.x
- Miura M, 2008, THER DRUG MONIT, V30, P46, DOI 10.1097/FTD.0b013e31816337b7
- PEREIRA L, 2005, AM J TRANSPLANT S5, V11, P466
- Rupprecht K, 2009, J CLIN PHARMACOL, V49, P1196, DOI 10.1177/0091270009344988
- Sachs George, 2010, Curr Gastroenterol Rep, V12, P437, DOI 10.1007/s11894-010-0149-5
- Schaier M, 2010, RHEUMATOLOGY, V49, P2061, DOI 10.1093/rheumatology/keq238
- Tonshoff B, 2011, TRANSPLANT REV-ORLAN, V25, P78, DOI 10.1016/j.trre.2011.01.001
- van Gelder T, 2008, TRANSPLANTATION, V86, P1043, DOI [10.1097/TP.0b013e318186f98a, 10.1097/TP.Gb013e318186f98a]